Pharmaceutical Executive
Because of the European Union's country-by-country drug price controls, enterprising wholesalers often buy prescription drugs in nations that keep prices low and resell them in countries that allow higher prices. Sanofi-Synthelabo's Plavix costs $55 in France but is resold for $79 in England. That long-standing practice, known as parallel trade, costs the pharma industry an estimated $3 billion in lost profits each year.
Because of the European Union's country-by-country drug price controls, enterprising wholesalers often buy prescription drugs in nations that keep prices low and resell them in countries that allow higher prices. Sanofi-Synthelabo's Plavix costs $55 in France but is resold for $79 in England. That long-standing practice, known as parallel trade, costs the pharma industry an estimated $3 billion in lost profits each year.
European authorities overruled previous industry attempts to block parallel trading, so pharma companies have begun restricting supplies to meet local needs only, according to formulas based on prior demand and anticipated growth. Countries will receive just enough product to meet demand so that no surplus exists for wholesalers to buy and resell. GlaxoSmithKline, Eli Lilly, Wyeth, and Sanofi have already imposed such quotas.
National governments, which pay for most European prescription products, and patients who buy drugs on their own currently benefit from the low prices provided by parallel trade and will have to pay more as a result of the quotas. One concern is possible shortages in countries with lower prices because wholesalers may use remaining supplies to profit from exports.
Parallel trade is not a global phenomenon. In the United States it's illegal to import pharmaceuticals for resale, although individuals can purchase lower priced drugs in foreign countries for personal use.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.